Abstract
HNSCC is a heterogeneous group of tumors located in the oral cavity, oropharynx, hypopharynx and larynx. Originally, tobacco and alcohol exposures were the main risk factors for HNSCC. In the last two decades, HPV infections have been identified as a risk factor for HNSCC, especially for oropharyngeal tumors. Whereas the HPV-induced oropharyngeal carcinomas predominantly express the HPV16 related E6 and E7 oncoproteins, the HPV-negative HNSCC are associated with an overexpression of p53. However, if the therapy successes for HPV-negative and HPV-positive HNSCCs are compared, there are significantly higher total survival rates for HPV-positive oropharyngeal tumors compared to HPV-negative tumors. It is important to understand this phenomenon in order to improve and adapt therapy concepts.
Access provided by CONRICYT-eBooks. Download chapter PDF
Similar content being viewed by others
Keywords
1 Cancer Immunology and HPV
HNSCC is a heterogeneous group of tumors located in the oral cavity, oropharynx, hypopharynx and larynx. Originally, tobacco and alcohol exposures were the main risk factors for HNSCC. In the last two decades, HPV infections have been identified as a risk factor for HNSCC, especially for oropharyngeal tumors, with the tonsil area being the most commonly affected area with 45–70 % HPV-positive cases (Mellin et al. 2002; Ritta et al. 2013).
More than 180 papilloma viruses have been identified to date, with approximately 120 genotypes isolated from humans. Whereas the HPV-induced oropharyngeal carcinomas predominantly express the HPV16 related E6 and E7 oncoproteins, the HPV-negative HNSCC are associated with an overexpression of p53 (Bernard et al. 2010).
However, if the therapy successes for HPV-negative and HPV-positive HNSCCs are compared, there are significantly higher total survival rates for HPV-positive oropharyngeal tumors compared to HPV-negative tumors (Gillison 2008; Ragin and Taioli 2007). It is important to understand this phenomenon in order to improve and adapt therapy concepts.
2 Immune Cell Infiltrations
Human solid tumor tissues are known to be infiltrated by various kinds of immune cells which are modulated within the tumor microenvironment (Hartmann et al. 2003; Heimdal et al. 2000; Pries and Wollenberg 2006; Veltri et al. 1986).
Several HPV-related immunologic features have been described in HNSCC.
In general, HPV-positive tumors have been shown to possess characteristic immune cell infiltrates compared to HPV-negative HNSCC. Recently, Partlova et al. 2015 have shown that HPV-positive tumors were infiltrated by significantly higher numbers of IFNgC CD8C T lymphocytes, IL-17C CD8C T lymphocytes, myeloid dendritic cells and proinflammatory chemokines. Furthermore, HPV-positive tumors had significantly lower expression of COX2 mRNA and higher expression of PD1 mRNA (Partlova et al.).
Spanos et al. 2009 have shown, for human and murine HPV-transformed cell lines, that neither radiation nor cisplatin therapy cured immune-incompetent mice, whereas in vivo, HPV-positive tumors were more sensitive to radiation and cisplatin treatment. Surprisingly, adoptive transfer of wild-type immune cells into immune-incompetent mice restored HPV-positive tumor clearance with cisplatin therapy. These data suggest that HPV-positive tumors are not more curable because of an increased epithelial sensitivity to cisplatin or radiation therapy, but because of an HPV-related immunity (Spanos et al. 2009).
These implications of a HPV-related immunity were corroborated by a study with an unselected group of 50 patients with HNSCC, where T lymphocytes were isolated from tumors and lymph nodes. Comprehensive investigations of the HPV16-specific T cell responses revealed a broad repertoire of CD41 T helper type 1 and type 2 cells, CD41 regulatory T cells and CD81 T cells reactive to HPV16. Heusinkveld et al. identified circulating HPV16-specific T cells in 63.6 % of the HPV-positive HNSCC, but only in 24.1 % of the HPV-negative HNSCC (Heusinkveld et al. 2012).
Similarly, Albers et al. found increased levels of T cells toward HPV16 E7 in HPV-positive HNSCC patients (Albers et al. 2005).
The local presence of HPV16-specific T cell immunity in HPV16-induced HNSCC was underlined by an additional study, which demonstrated increased infiltrations of CD3+ and FoxP3+ T cells in correlation with higher HPV16 copy numbers in solid HNSCC (Ritta et al. 2013).
Correspondingly, it has been shown that targeting CD137, which is an inducible receptor on activated T lymphocytes, synergizes with cisplatin and radiation therapy in HPV-positive HNSCC (Lucido et al. 2014).
Furthermore, increased amounts of effector memory and effector T cells were found in patients with human HPV-positive oropharyngeal squamous cell carcinomas, suggesting a virus-induced T cell activation (Turksma et al. 2013).
In addition, increased numbers of different types of antigen presenting cells such as myeloid dendritic cells (mDC), plasmacytoid dendritic cells (pDC), macrophages and monocytes have been found in HPV-associated HNSCC (Levovitz et al.). Comprehensive immune profiling using qRT-PCR and immunohistochemistry identified a significantly increased infiltration of HPV-positive HNSCC by CD20+ B cells, as well as by invasive margin FoxP3+ Treg (Russell et al. 2013).
Similar findings have recently been demonstrated for HPV-related cervical cancers, where the HPV infection was associated with macrophage differentiation, a compromised cellular immune response, an abnormal imbalance between type 1 T–helper cells (Th1) and Th2 cells, regulatory T cell infiltration, and downregulated DC activation and maturation (Song et al. 2015).
3 Microenvironment Modulation
All these different types of immune cells are known to release numerous cytokines and inflammatory mediators with proangiogenic and prometastatic effects, and the potential to drive tumor progression.
For example, IL-1 is produced by monocytes, macrophages, dendritic cells and various other cells, and in HNSCC IL-1α and IL-1β have also been demonstrated to modestly induce the production of gelatines, which are family members of the matrix metalloproteinases (MMPs) and contribute to tumor invasion and metastasis (Mann et al. 1995 ).
IL-1α was furthermore identified to promote the transcriptional activator NF-κB which is known to participate in various aspects of cancer induction and maintenance (Wolf et al. 2001).
TGFβ is known to inhibit the proliferation and function of T and B lymphocytes as well as the function of macrophages (Chen et al. 1999; Mann et al. 1992).
Levovitz et al. (2014) have shown an overexpression of TGFßR1 in HPV-related oropharyngeal cancer and cervical cancer, which implicates TGFβR1/TGFβ signaling in the development of both cancer types (Levovitz et al. 2014).
In addition, HNSCC cell lines have recently been demonstrated to express IL-18 which is a proinflammatory cytokine that plays an important role in NK cell activation and Th1 cell response (Martone et al. 2004).
For HPV-positive tumors, the critical parameter to escape from efficient immune responses is the interference of HPV with the expression of interferons (IFNs), which are produced by virus-infected cells and reveal immuno-stimulatory properties. Furthermore, HPV interacts with antigen presentation to reduce adaptive immune responses and to downregulate HLA class I (Ferris 2015).
Thus, the cancer immunology has a huge impact on the tumor progression and its therapy response, and has to be distinguished between HPV-positive and HPV-negative HNSCCs.
In addition to the mentioned HPV-specific T cell profiles, the Warburg phenomenon has been discussed concerning its effect on antitumoral immune responses, since the accumulation of tumor-derived lactate inhibits cytotoxic T cells. An immunohistochemical analysis of oropharyngeal carcinomas showed an enhanced antitumoral immune response (CD8/CD4 ratio) together with increased levels of proteins involved in transmembranous metabolite transportation (GLUT1 and CD147) and respiratory metabolism (COX5B) in HPV-positive HNSCC (Krupar et al. 2014).
Concerning the incurrence of HPV-related HNSCC, several publications discussed HPV-specific humoral immune responses. Indeed, the presence of antibodies to HPV proteins E6 and/or E7 has been shown to be associated with a significant increased risk for oropharyngeal cancer. Antibodies to HPV16 have been detected in some patients more than 15 years before their cancer diagnosis (Gillison et al. 2012).
4 Immunotherapeutic Approaches
Generally, immune therapy provides active and passive as well as specific and unspecific forms of antitumoral activity. The currently closest approach to clinical application is different HPV-related vaccination approaches. Several approaches are under development in HNSCC, using specific peptide vaccines such as melanoma antigen A3/HPV-16 peptide (NCT00257738), HPV-16 E7 Listeria vaccine (Sewell et al. 2004) or vaccinia-based E6/E7 vaccine (Davidson et al. 2004).
Furthermore, adoptive T cell transfer is currently evaluated for HNSCC immunotherapy, where T cells are first removed from the patient before they get reintroduced after specific modifications in order to enhance their activity against HPV-associated head and neck cancer (NCT01585428) (Ferris 2015).
In summary, the current state of knowledge suggests that the presence of HPV may induce an increased immune response and may be responsible for a more favorable prognosis of HPV-positive HNSCC.
References
Albers A, Abe K, Hunt J, Wang J, Lopez-Albaitero A, Schaefer C, Gooding W, Whiteside TL, Ferrone S, DeLeo A, Ferris RL (2005) Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 65:11146–11155
Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM (2010) Classification of papilloma viruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401:70–79
Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher LL, Van Waes C (1999) Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5:1369–1379
Davidson EJ, Faulkner RL, Sehr P, Pawlita M, Smyth LJ, Burt DJ, Tomlinson AE, Hickling J, Kitchener HC, Stern PL (2004) Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine 22:2722–2729
Ferris RL (2015) Immunology and Immunotherapy of head and neck cancer. J Clin Oncol 33:3293–3304
Gillison ML (2008) Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination. J Adolesc Health 43:S52–S60
Gillison ML, Alemany L, Snijders PJ, Chaturvedi A, Steinberg BM, Schwartz S, Castellsague X (2012) Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 30(5):F34–F54
Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B, Giese T, Gires O, Endres S, Hartmann G (2003) Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res 63:6478–6487
Heimdal JH, Aarstad HJ, Olofsson J (2000) Peripheral blood T-lymphocyte and monocyte function and survival in patients with head and neck carcinoma. Laryngoscope 110:402–407
Heusinkveld M, Goedemans R, Briet RJ, Gelderblom H, Nortier JW, Gorter A, Smit VT, Langeveld AP, Jansen JC, van der Burg SH (2012) Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Int J Cancer 131:E74–E85
Krupar R, Robold K, Gaag D, Spanier G, Kreutz M, Renner K, Hellerbrand C, Hofstaedter F, Bosserhoff AK (2014) Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different. Virchows Arch 465:299–312
Levovitz C, Chen D, Ivansson E, Gyllensten U, Finnigan JP, Alshawish S, Zhang W, Schadt EE, Posner MR, Genden EM, Boffetta P, Sikora AG (2014) TGFbeta receptor 1: an immune susceptibility gene in HPV-associated cancer. Cancer Res 74:6833–6844
Lucido CT, Vermeer PD, Wieking BG, Vermeer DW, Lee JH (2014) CD137 enhancement of HPV positive head and neck squamous cell carcinoma tumor clearance. Vaccines (Basel) 2:841–853
Mann EA, Spiro JD, Chen LL, Kreutzer DL (1992) Cytokine expression by head and neck squamous cell carcinomas. Am J Surg 164:567–573
Mann EA, Hibbs MS, Spiro JD, Bowik C, Wang XZ, Clawson M, Chen LL (1995) Cytokine regulation of gelatinase production by head and neck squamous cell carcinoma: the role of tumor necrosis factor-alpha. Ann Otol Rhinol Laryngol 104:203–209
Martone T, Bellone G, Pagano M, Beatrice F, Palonta F, Emanuelli G, Cortesina G (2004) Constitutive expression of interleukin-18 in head and neck squamous carcinoma cells. Head Neck 26:494–503
Mellin H, Dahlgren L, Munck-Wikland E, Lindholm J, Rabbani H, Kalantari M, Dalianis T (2002) Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer 102:152–158
Partlova S, Boucek J, Kloudova K, Lukesova E, Zabrodsky M, Grega M, Fucikova J, Truxova I, Tachezy R, Spisek R, Fialova A (2015) Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. Oncoimmunology 4:e965570
Pries R, Wollenberg B (2006) Cytokines in head and neck cancer. Cytokine Growth Factor Rev 17:141–146
Ragin CC, Taioli E (2007) Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 121:1813–1820
Ritta M, Landolfo V, Mazibrada J, De Andrea M, Dell‘Oste V, Caneparo V, Peretti A, Giordano C, Pecorari G, Garzaro M, Landolfo S (2013) Human papillomavirus tumor-infiltrating T-regulatory lymphocytes and P53 codon 72 polymorphisms correlate with clinical staging and prognosis of oropharyngeal cancer. New Microbiol 36:133–144
Russell S, Angell T, Lechner M, Liebertz D, Correa A, Sinha U, Kokot N, Epstein A (2013) Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma. Head Neck Oncol 5:24
Sewell DA, Shahabi V, Gunn GR 3rd, Pan ZK, Dominiecki ME, Paterson Y (2004) Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7. Cancer Res 64:8821–8825
Song D, Li H, Dai J (2015) Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer. Oncol Lett 10:600–606
Spanos WC, Nowicki P, Lee DW, Hoover A, Hostager B, Gupta A, Anderson ME, Lee JH (2009) Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 135:1137–1146
Turksma AW, Bontkes HJ, van den Heuvel H, de Gruijl TD, von Blomberg BM, Braakhuis BJ, Leemans CR, Bloemena E, Meijer CJ, Hooijberg E (2013) Effector memory T-cell frequencies in relation to tumour stage, location and HPV status in HNSCC patients. Oral Dis 19:577–584
Veltri RW, Rodman SM, Maxim PE, Baseler MW, Sprinkle PM (1986) Immune complexes, serum proteins, cell-mediated immunity, and immune regulation in patients with squamous cell carcinoma of the head and neck. Cancer 57:2295–2308
Wolf JS, Chen Z, Dong G, Sunwoo JB, Bancroft CC, Capo DE, Yeh NT, Mukaida N, Van Waes C (2001) IL (interleukin)-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 7:1812–1820
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Wollenberg, B. (2017). Cancer Immunology and HPV. In: Golusiński, W., Leemans, C., Dietz, A. (eds) HPV Infection in Head and Neck Cancer. Recent Results in Cancer Research, vol 206. Springer, Cham. https://doi.org/10.1007/978-3-319-43580-0_19
Download citation
DOI: https://doi.org/10.1007/978-3-319-43580-0_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43578-7
Online ISBN: 978-3-319-43580-0
eBook Packages: MedicineMedicine (R0)